Koninklijke Philips (NYSE:PHG – Get Free Report) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company.
A number of research analysts recently commented on PHG shares. StockNews.com lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Jefferies Financial Group upgraded Koninklijke Philips from an “underperform” rating to a “hold” rating in a report on Tuesday, October 29th.
Read Our Latest Report on Koninklijke Philips
Institutional Trading of Koninklijke Philips
Koninklijke Philips Stock Up 0.1 %
Koninklijke Philips stock opened at $26.40 on Friday. Koninklijke Philips has a 52 week low of $19.49 and a 52 week high of $32.91. The stock has a market cap of $24.81 billion, a price-to-earnings ratio of -62.84, a PEG ratio of 0.91 and a beta of 0.77. The company’s 50-day moving average price is $29.64 and its two-hundred day moving average price is $28.25. The company has a current ratio of 1.16, a quick ratio of 0.74 and a debt-to-equity ratio of 0.60.
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Featured Stories
- Five stocks we like better than Koninklijke Philips
- Investing in Travel Stocks Benefits
- Tesla Investors Continue to Profit From the Trump Trade
- How to Calculate Stock Profit
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.